Publications by authors named "Koji Date"

Claim this Profile
C
Clinical impact of cancer cachexia on the outcome of patients with non-small cell lung cancer with PD-L1 tumor proportion scores of ≥50% receiving pembrolizumab monotherapy versus immune checkpoint inhibitor with chemotherapy.
Hayato Kawachi, Tadaaki Yamada, Motohiro Tamiya, Yoshiki Negi, Takashi Kijima, Koji Date

Oncoimmunology· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of Poor Prognostic Factors and Treatment Strategies in Platinum-Based Systemic Therapy After EGFR-TKI Failure in Patients With Advanced Nonsmall Cell Lung Cancer Harboring EGFR Mutations.
Tae Hata, Tadaaki Yamada, Naoki Furuya, Hisashi Tanaka, Akihiro Yoshimura, Koji Date

Clin Lung Cancer· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic factors in patients with interstitial lung disease treated with nintedanib: a multicenter retrospective study in Japan.
Shiho Goda, Tadaaki Yamada, Yasuhiro Goto, Sayaka Uda, Akira Nakao, Koji Date

Sci Rep· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selecting optimal immunotherapy based on inflammation in stage IV PD-L1 ≥50% gene mutation-negative non-small cell lung cancer: pembrolizumab monotherapy versus combination chemoimmunotherapy.
Yusuke Kunimatsu, Naoya Nishioka, Tadaaki Yamada, Hayato Kawachi, Motohiro Tamiya, Koji Date

Transl Lung Cancer Res· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world treatment outcomes before and after chemoimmunotherapy approval in EGFR-mutant NSCLC after EGFR-TKI failure: a Japanese cohort study.
Kenji Morimoto, Tadaaki Yamada, Naoki Furuya, Hisashi Tanaka, Akihiro Yoshimura, Koji Date

Int J Clin Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of EGFR Mutation Subtypes on Response to Chemoimmunotherapy and Chemotherapy in Non-Small-Cell Lung Cancer After EGFR-TKI Failure.
Kenji Morimoto, Tadaaki Yamada, Naoki Furuya, Hisashi Tanaka, Akihiro Yoshimura, Koji Date

Target Oncol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Y
YAP Regulates HER3 Signaling-Driven Adaptive Resistance to RET Inhibitors in RET-Aberrant Cancers.
Yuki Katayama, Tadaaki Yamada, Keiko Tanimura, Hayato Kawachi, Masaki Ishida, Koji Date

Clin Cancer Res· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploration of clinical Biomarkers for guiding treatment selection between chemotherapy and combination therapy with Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel in EGFR-Mutant NSCLC patients after EGFR-TKI Therapy: The SPIRAL-STEP study.
Kenji Morimoto, Tadaaki Yamada, Naoki Furuya, Hisashi Tanaka, Akihiro Yoshimura, Koji Date

Lung Cancer· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Depth of response and treatment outcomes of immune checkpoint inhibitor-based therapy in patients with advanced non-small cell lung cancer and high PD-L1 expression: An exploratory analysis of retrospective multicenter cohort.
Yusuke Tachibana, Kenji Morimoto, Tadaaki Yamada, Hayato Kawachi, Motohiro Tamiya, Koji Date

Invest New Drugs· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Unraveling the influence of TTF-1 expression on immunotherapy outcomes in PD-L1-high non-squamous NSCLC: a retrospective multicenter study.
Naoya Nishioka, Hayato Kawachi, Tadaaki Yamada, Motohiro Tamiya, Yoshiki Negi, Koji Date

Front Immunol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic impact of clinical factors for immune checkpoint inhibitor with or without chemotherapy in older patients with non-small cell lung cancer and PD-L1 TPS ≥ 50.
Shota Takei, Hayato Kawachi, Tadaaki Yamada, Motohiro Tamiya, Yoshiki Negi, Koji Date

Front Immunol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chemoimmunotherapy Versus Pembrolizumab as a First-Line Treatment for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression: Focus on the Role of Performance Status.
Kenji Morimoto, Tadaaki Yamada, Hayato Kawachi, Motohiro Tamiya, Yoshiki Negi, Koji Date

Target Oncol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Efficacy and Safety of First- or Second-Generation EGFR-TKIs after Osimertinib Resistance for EGFR Mutated Lung Cancer: A Prospective Exploratory Study.
Kenji Morimoto, Tadaaki Yamada, Takayuki Takeda, Shinsuke Shiotsu, Koji Date

Target Oncol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Concomitant Proton Pump Inhibitor Use With Pembrolizumab Monotherapy vs Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With Non-Small Cell Lung Cancer.
Hayato Kawachi, Tadaaki Yamada, Motohiro Tamiya, Yoshiki Negi, Yasuhiro Goto, Koji Date

JAMA Netw Open· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prospective Observational Study Evaluating the Prognostic Value of the G8 Screening Tool for Extensive-Stage Small Cell Lung Cancer Patients Who Received Programmed Death-Ligand 1 Inhibitor plus Platinum-Etoposide Chemotherapy.
Kenji Morimoto, Tadaaki Yamada, Takayuki Takeda, Shinsuke Shiotsu, Koji Date

Drugs Aging· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early Tumor Shrinkage as a Predictor of Favorable Treatment Outcomes in Patients With Extensive-Stage SCLC Who Received Programmed Cell Death-Ligand 1 Inhibitor Plus Platinum-Etoposide Chemotherapy: A Prospective Observational Study.
Masaki Ishida, Kenji Morimoto, Tadaaki Yamada, Takayuki Takeda, Shinsuke Shiotsu, Koji Date

JTO Clin Res Rep· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase II Trial on Osimertinib as a First-Line Treatment for EGFR Mutation-Positive Advanced NSCLC in Elderly Patients: The SPIRAL-0 Study.
Yusuke Chihara, Takayuki Takeda, Yasuhiro Goto, Yoichi Nakamura, Yuko Tsuchiya-Kawano, Koji Date

Oncologist· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Programmed Death-Ligand 1 Inhibitor Plus Platinum-Etoposide Chemotherapy in Patients With Extensive-Stage SCLC: A Prospective Observational Study.
Kenji Morimoto, Tadaaki Yamada, Takayuki Takeda, Shinsuke Shiotsu, Koji Date

JTO Clin Res Rep· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II Study of S-1 and Paclitaxel Combination Therapy in Patients with Previously Treated Non-Small Cell Lung Cancer.
Yusuke Chihara, Akihiro Yoshimura, Koji Date, Yoshizumi Takemura, Nobuyo Tamiya

Oncologist· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Retrospective analysis of docetaxel in combination with ramucirumab for previously treated non-small cell lung cancer patients.
Akihiro Yoshimura, Tadaaki Yamada, Yusuke Okuma, Rui Kitadai, Takayuki Takeda, Koji Date

Transl Lung Cancer Res· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of S-1 plus paclitaxel combination therapy as a first-line treatment in elderly patients with advanced non-small cell lung cancer.
Yusuke Chihara, Koji Date, Yoshizumi Takemura, Nobuyo Tamiya, Yoshihito Kohno

Invest New Drugs· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase II Study of S-1 and Paclitaxel Combination Therapy as a First-Line Treatment in Elderly Patients with Advanced Non-Small Cell Lung Cancer.
Akihiro Yoshimura, Yusuke Chihara, Koji Date, Nobuyo Tamiya, Yoshizumi Takemura

Oncologist· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Feasibility Study of Sequentially Alternating EGFR-TKIs and Chemotherapy for Patients with Non-small Cell Lung Cancer.
Yoshizumi Takemura, Yusuke Chihara, Yoshie Morimoto, Keiko Tanimura, Tatsuya Imabayashi, Koji Date

Anticancer Res· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[A case of microscopic polyangiitis with silicosis].
Masaki Nakanishi, Koji Date, Yasunori Koyama, Mikio Ueda, Taichiro Arimoto

Nihon Kokyuki Gakkai Zasshi· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Case of thymic carcinoid accompanied by adenocarcinoma of the lung].
Yutaka Kubota, Yusuke Chihara, Koji Date, Takahiro Yamada, Hiroshi Hara

Nihon Kokyuki Gakkai Zasshi· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis